Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer

Non-small cell lung cancer (NSCLC) patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation are associated with significant clinical heterogeneity and a poor prognosis to standard NSCLC therapies such as surgical resection, radiotherapy, chemotherapies, and targeted medicines. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yunchang, Hu, Lanlin, Peng, Xinhao, Xu, Huasheng, Tang, Bo, Xu, Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992585/
https://www.ncbi.nlm.nih.gov/pubmed/35582540
http://dx.doi.org/10.20517/cdr.2021.102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992585/
https://www.ncbi.nlm.nih.gov/pubmed/35582540
http://dx.doi.org/10.20517/cdr.2021.102

Ejemplares similares